Celgene reiterates stance on Kyle Bass IPRs

29-09-2015

Celgene reiterates stance on Kyle Bass IPRs

Photo: Courtesy of Celgene ( Celgene Logo, https://www.celgene.com/media-library/celgene-logo/)

Biopharmaceutical company Celgene has reiterated its stance on the inter partes review (IPR) petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision.


Celgene, Patent Trial and Appeal Board, PTAB, USPTO, Coalition for Affordable Drugs, inter partes reviews, patents, Kyle Bass

LSIPR